Therefore, we applied network pharmacology analysis to systematically excavate the action targets of SGLT2 inhibitors in DM with HF to analyze the biological pathways involved, which will lay a good foundation for further in-depth exploration of the mechanism of SGLT2 inhibitors acting on DM with HF. The gene discussed is SLC5A2; the disease is diabetes mellitus.